1H-Pyrazole-3-carboxamide, 5-[1-[(4-fluorophenyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-(3-pyridinylmethyl)- manufacturers
- SCD1 inhibitor-3
-
- $84.00
-
2026-07-17
- CAS:1282606-48-7
- Purity: 99.50%
- Supply Ability: 10g
|
| | 1H-Pyrazole-3-carboxamide, 5-[1-[(4-fluorophenyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-(3-pyridinylmethyl)- Basic information |
| Product Name: | 1H-Pyrazole-3-carboxamide, 5-[1-[(4-fluorophenyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-(3-pyridinylmethyl)- | | Synonyms: | 1H-Pyrazole-3-carboxamide, 5-[1-[(4-fluorophenyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-(3-pyridinylmethyl)-;SCD1 inhibitor-3;FUN06487;5-{1-[(4-fluorophenyl)methyl]-5-oxo-4,5-dihydro-1H-1,2,4-triazol-4-yl}-N-[(pyridin-3-yl)methyl]-1H-pyrazole-3-carboxamide;SCD1 inhibitor-3, 10 mM in DMSO | | CAS: | 1282606-48-7 | | MF: | C19H16FN7O2 | | MW: | 393.37 | | EINECS: | | | Product Categories: | | | Mol File: | 1282606-48-7.mol | ![1H-Pyrazole-3-carboxamide, 5-[1-[(4-fluorophenyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-(3-pyridinylmethyl)- Structure](CAS/20210305/GIF/1282606-48-7.gif) |
| | 1H-Pyrazole-3-carboxamide, 5-[1-[(4-fluorophenyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-(3-pyridinylmethyl)- Chemical Properties |
| density | 1.47±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 125 mg/mL (317.77 mM) | | pka | 11.56±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | 1H-Pyrazole-3-carboxamide, 5-[1-[(4-fluorophenyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-(3-pyridinylmethyl)- Usage And Synthesis |
| Description | FUN06487, also known as SCD1 inhibitor-3, is a SCD1 inhibitor. This compound was first reported in WO 2011039358. This product has no formal name at the moment. | | Uses | SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1]. | | in vivo | SCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %[1].
SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1]. | Animal Model: | Lewis rats[1] | | Dosage: | 5 mg/kg | | Administration: | P.o.; 4 hours | | Result: | Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %. |
| Animal Model: | Lewis rats[1] | | Dosage: | 2~10 mg/kg | | Administration: | P.o.; 4 hours | | Result: | A dose-responsive reduction of plasma triglycerides desaturation index.
|
| | References | [1] Sun S, et al. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors. Bioorg Med Chem. 2015;23(3):455-465. DOI:10.1016/j.bmc.2014.12.014 |
| | 1H-Pyrazole-3-carboxamide, 5-[1-[(4-fluorophenyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-(3-pyridinylmethyl)- Preparation Products And Raw materials |
|